Bijal D. Shah, MD

A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.

Dr. Shah and faculty provide updates on emerging therapies, which exhibit promise for the treatment of relapsed or refractory acute lymphoblastic leukemia such as tisagenlecleucel and Obe-cel; obecabtagene autoleucel, preliminary outcomes of which were presented in the FELIX study at the 65th ASH Annual Meeting.

Dr. Shah and colleagues dissect the social determinants of health, including limited personal resources, frailty, distance to treatment facilities, therapeutic compliance, and other considerations that impact effective treatment sequencing for patients with relapsed or refractory ALL, including access to care and CAR-T cell availability.

A panel of experts discuss how to sequence BTK inhibitors and CAR T-cell therapies in patients with MCL.

Experts on mantle cell lymphoma discuss third-line treatment options available for patients.

Dr. Park and co-panelists review the patient and disease characteristics, including patient age, high pre-apheresis disease burden, and bridging response to inotuzumab or blinatumomab among other variables that might best support consideration of post-CART19 maintenance therapy.

Dr. Roloff and faculty assess outcomes from the retrospective, multicenter ROCCA analysis (Real-world Outcomes Collaborative of CAR-T in Adult ALL) and propose some social determinants of health SDoH variables that bear further investigation.

Experts on mantle cell lymphoma discuss second-line treatment options available for patients.

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.

Dr. Roloff and colleagues offer expert opinion on optimizing treatment sequences for patients with relapsed or refractory ALL who have received two or more prior lines of therapy and the disease and patient factors that inform their treatment plans.

Panelists evaluate PFS, OS, and the prognostic significance of negative MRD.

Experts on mantle cell lymphoma discuss first-line treatment options available for patients.

Laurie Sehn, MD, and Bijal Shah, MD, discuss remaining unmet needs for patients with relapsed/refractory FL.

Dr. Bijal and colleagues discuss the objectives, clinical outcomes, and safety profile of the Phase 2 ZUMA 3 clinical trial, which evaluated treatment of adult patients with relapsed or refractory, B-precursor, acute lymphoblastic leukemia with the anti-CD-19/anti-CD20 bispecific CAR-T cell therapy, KTE-X19 (brexucabtagene autoleucel).

Drs. Roloff, Park, and Shah provide a brief overview of the current, CAR-T cell therapeutic landscape for relapsed or refractory acute lymphoblastic leukemia in adults with a particular focus on those who have completed two or more lines of prior therapy.

Faculty review the objectives of the 2023 ASH Insights Program on the Efficacy and Safety of Brexucabtagene Autoleucel CART19 Cell Therapy in Adults with Advanced Acute Lymphoblastic Leukemia.

Peter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.

Jennifer Crombie, MD, discusses how to choose CAR T-cells as third-line and beyond therapy for FL.

A panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.

Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.

Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.

Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.

Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.

Experts on follicular lymphoma discuss second-line treatment options available for patients.

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline FL.

Panelist introductions by Gregory Roloff, MD from the University of Chicago Comprehensive Cancer Center, Chicago, Illinois; Jae Park, MD, Memorial Sloan Kettering Cancer Center, New York, New York; and Bijal Shah, MD, from the Moffitt Cancer Center, Tampa, Florida.

Experts on follicular lymphoma discuss first-line treatment options available for patients.

Hagop M. Kantarjian, MD, and Bijal D. Shah, MD, MS, delve into upcoming strategies for handling Philadelphia-chromosome positive acute lymphoblastic leukemia, considering recent breakthroughs.

Insights on real-world ponatinib treatment strategies and safety in Philadelphia-positive acute lymphoblastic leukemia are provided by Hagop Kantarjian, MD, and Bijal D. Shah, MD, MS.

Expert hematologist-oncologists consider how the PhALLCON trial elucidates the safety of ponatinib in Ph+ ALL, highlighting comparable toxicity rates and favorable efficacy endpoints.